Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × abiraterone × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 69 Neoplasm Metastasis 8 Prostatic Neoplasms, Castration-Resistant 5 Metastatic Castration-Resistant Prostate Cancer 3 Carcinoma, Non-Small-Cell Lung 3 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Primary Myelofibrosis 2 Pancreatic Neoplasms 2 Neoplasms 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Multiple Myeloma 2 Metastatic Castration-resistant Prostate Cancer (mCRPC) 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Thrombocytosis 1 Prostatic Diseases 1 Prostate Cancer Metastatic Disease 1 Prostate Adenocarcinoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Ovarian Neoplasms 1 Oligometastatic Prostate Carcinoma 1 Oligo-metastatic Prostate Carcinoma 1 Newly Diagnosed Oligometastatic Prostate Cancer 1 Neoplasms by Site 1

Interventions

pembrolizumab 6 Radiosurgery 5 Docetaxel 4 enzalutamide 3 Radiotherapy 3 Everolimus 3 Androgen Antagonists 3 relugolix 2 luprolide acetate gel depot 2 darolutamide 2 Surveys and Questionnaires 2 Standard of Care 2 Radiofrequency Ablation 2 Panobinostat 2 Leuprolide 2 Abiraterone Acetate 2 trastuzumab deruxtecan 1 talazoparib 1 spartalizumab 1 siremadlin 1 sipuleucel-T 1 sargramostim 1 resiquimod 1 poly ICLC 1 olaparib 1 liposomal doxorubicin 1 ixabepilone 1 gallium 68 PSMA-11 1 apatinib 1 apalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06592924 2026-01-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡